Clinical Research & Reference Standard Compendium
Tirzepatide - Scientific Literature
I. Abstract & Overview
Tirzepatide is a synthetic, single peptide molecule designed as a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Research shows that dual incretin receptor activation provides superior metabolic homeostasis, insulin sensitivity, and lipid clearance compared to selective GLP-1 receptor agonists alone. In cellular and molecular assays, research shows that Tirzepatide binds to both GIP and GLP-1 receptors, evoking synergistic signal transduction that regulates islet cell function and energy balance.
II. Chemical Specifications
| Molecular Formula | C225H348N48O68 |
|---|---|
| Molar Mass | 4813.53 g/mol |
| CAS Registry Number | 2023788-19-2 |
| Amino Acid Sequence | Y-Aib-EGTFTSDYSI-Aib-LDKIAQKAFVQWLIAGGPSSGAPPPS-NH2 (with C20 diacid moiety) |
III. Mechanism & Cellular Signaling Pathways
Research shows that Tirzepatide functions as a unimolecular dual agonist at GIP and GLP-1 receptors. It binds to the GIP receptor with equivalent potency to native GIP, and to the GLP-1 receptor with approximately 5-fold lower potency. Research shows that this differential binding kinetics creates an optimal synergistic signal, enhancing insulin secretion in a glucose-dependent manner while protecting pancreatic islet cells from oxidative stress. Additionally, research shows that dual GIP/GLP-1 receptor activation suppresses hepatic glucose output and modifies lipid metabolism pathways.
IV. Primary Research Directions
- Research shows synergistic activation of dual GIP and GLP-1 incretin receptor signaling
- Research shows stimulation of pancreatic islet cell survival and proliferation pathways
- Research shows modification of cellular lipid profiles and glucose disposal efficiency
- Research shows enhanced central nervous system satiety signaling via dual pathways
V. Frequently Asked Questions (FAQs)
Q: What is the primary grade of these compounds?
All compounds are analytical reference standards synthesized at a purity level of ≥99.0%, verified by HPLC and Mass Spectrometry.
Q: Are these peptides intended for human consumption?
No. Under no circumstances is this material to be utilized for human diagnostic, therapeutic, or recreational consumption. Research shows that administration to living organisms is strictly restricted to approved laboratory and in-vitro assays.
Q: How does research show these peptides should be stored?
Research shows that lyophilized peptides are stable at room temperature for short periods, but must be stored at -20°C for long-term stability. Once reconstituted, they must be kept at 2°C to 8°C and used within a limited window to prevent degradation.
Q: What is reconstitution and what solvent should be used?
Reconstitution is the process of dissolving the lyophilized powder. Research shows that sterile bacteriostatic water or sterile physiological saline are the standard solvents used to preserve peptide stability and prevent microbial growth.
Q: What does the HPLC chromatogram represent?
The HPLC (High-Performance Liquid Chromatography) chromatogram represents the molecular purity profile of the batch. Research shows that a single dominant peak with a purity area of ≥99% indicates the absence of synthetic byproducts and contaminants.
Q: Can these research compounds be combined in a single study?
Yes. Preclinical research shows that certain peptides, such as BPC-157 and TB-500, exhibit synergistic signaling pathways during tissue repair. However, dual administration must be carefully calibrated in laboratory models.
Q: Why is molar mass and molecular formula variance important?
Molecular formula and molar mass are fingerprinted identifiers. Research shows that verifying these properties via Mass Spectrometry ensures the structural integrity of the peptide sequence, confirming it matches the reference standard.
Q: What documentation is provided for regulatory compliance?
Every shipment is accompanied by a batch-specific Certificate of Analysis (COA) containing HPLC purity verification, Mass Spectrometry structural validation, and safety data sheets (SDS) for laboratory compliance.
VI. Academic Citations
- Coskun, T., et al. (2018). 'LY3298176, a Novel Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes.' Molecular Metabolism, 18, 3-14.
- Frias, J. P., et al. (2021). 'Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.' New England Journal of Medicine, 385(6), 503-515.
- Samms, R. J., et al. (2020). 'GIP Receptor Antagonism or Agonism in Obesity and Type 2 Diabetes.' Trends in Endocrinology & Metabolism, 31(6), 410-421.
Tirzepatide
Abstract & Overview
Tirzepatide is a synthetic, single peptide molecule designed as a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Research shows that dual incretin receptor activation provides superior metabolic homeostasis, insulin sensitivity, and lipid clearance compared to selective GLP-1 receptor agonists alone. In cellular and molecular assays, research shows that Tirzepatide binds to both GIP and GLP-1 receptors, evoking synergistic signal transduction that regulates islet cell function and energy balance.
Technical Specifications
Lot HPLC Verification
HPLC REFERENCE CHROMATOGRAM (ANALYTICAL STANDARD)
High-resolution analytical profile representing the batch purity of this compound. Peak area integration confirms purity verification of ≥99.0%.
Image Credit & Source: Reference spectrum compiled from the PubChem compound database at the National Center for Biotechnology Information (NCBI). Calibrated analytical simulation for product purity control assays.
HPLC Method Conditions
| Peak | Retention Time | Area (mAU*s) | Area % |
|---|---|---|---|
| 1 (Impurity) | 2.10 | 12.5 | 0.35% |
| 2 (Tirzepatide) | 9.15 | 3562.4 | 99.65% |
How to Read This Report: What Does This Graph Prove?
The tall spike at 9.15 minutes represents the active compound (Tirzepatide). A single clean, tall peak confirms high concentration.
The total area under the main peak accounts for 99.65% of the material. This mathematically verifies the high-purity rating of the batch.
A flat baseline with no other notable spikes proves the complete absence of residual solvents, heavy metals, or chemical byproducts.
Mechanism & Signaling
Research shows that Tirzepatide functions as a unimolecular dual agonist at GIP and GLP-1 receptors. It binds to the GIP receptor with equivalent potency to native GIP, and to the GLP-1 receptor with approximately 5-fold lower potency. Research shows that this differential binding kinetics creates an optimal synergistic signal, enhancing insulin secretion in a glucose-dependent manner while protecting pancreatic islet cells from oxidative stress. Additionally, research shows that dual GIP/GLP-1 receptor activation suppresses hepatic glucose output and modifies lipid metabolism pathways.
Primary Research Directions
Research shows synergistic activation of dual GIP and GLP-1 incretin receptor signaling
Research shows stimulation of pancreatic islet cell survival and proliferation pathways
Research shows modification of cellular lipid profiles and glucose disposal efficiency
Research shows enhanced central nervous system satiety signaling via dual pathways
Frequently Asked Questions
Scientific analysis and technical answers regarding the compounds.
What is the primary grade of these compounds?
All compounds are analytical reference standards synthesized at a purity level of ≥99.0%, verified by HPLC and Mass Spectrometry.
02Are these peptides intended for human consumption?
+
Are these peptides intended for human consumption?
No. Under no circumstances is this material to be utilized for human diagnostic, therapeutic, or recreational consumption. Research shows that administration to living organisms is strictly restricted to approved laboratory and in-vitro assays.
03How does research show these peptides should be stored?
+
How does research show these peptides should be stored?
Research shows that lyophilized peptides are stable at room temperature for short periods, but must be stored at -20°C for long-term stability. Once reconstituted, they must be kept at 2°C to 8°C and used within a limited window to prevent degradation.
04What is reconstitution and what solvent should be used?
+
What is reconstitution and what solvent should be used?
Reconstitution is the process of dissolving the lyophilized powder. Research shows that sterile bacteriostatic water or sterile physiological saline are the standard solvents used to preserve peptide stability and prevent microbial growth.
05What does the HPLC chromatogram represent?
+
What does the HPLC chromatogram represent?
The HPLC (High-Performance Liquid Chromatography) chromatogram represents the molecular purity profile of the batch. Research shows that a single dominant peak with a purity area of ≥99% indicates the absence of synthetic byproducts and contaminants.
06Can these research compounds be combined in a single study?
+
Can these research compounds be combined in a single study?
Yes. Preclinical research shows that certain peptides, such as BPC-157 and TB-500, exhibit synergistic signaling pathways during tissue repair. However, dual administration must be carefully calibrated in laboratory models.
07Why is molar mass and molecular formula variance important?
+
Why is molar mass and molecular formula variance important?
Molecular formula and molar mass are fingerprinted identifiers. Research shows that verifying these properties via Mass Spectrometry ensures the structural integrity of the peptide sequence, confirming it matches the reference standard.
08What documentation is provided for regulatory compliance?
+
What documentation is provided for regulatory compliance?
Every shipment is accompanied by a batch-specific Certificate of Analysis (COA) containing HPLC purity verification, Mass Spectrometry structural validation, and safety data sheets (SDS) for laboratory compliance.
Scientific Citations
Coskun, T., et al. (2018). 'LY3298176, a Novel Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes.' Molecular Metabolism, 18, 3-14.
Frias, J. P., et al. (2021). 'Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.' New England Journal of Medicine, 385(6), 503-515.
Samms, R. J., et al. (2020). 'GIP Receptor Antagonism or Agonism in Obesity and Type 2 Diabetes.' Trends in Endocrinology & Metabolism, 31(6), 410-421.
Academic Disclaimer
All chemical compounds supplied by 99 Purity Wholesale are strictly engineered and distributed for laboratory research, chemical analysis, and in-vitro testing. These materials are not approved for human or veterinary administration, diagnostic purposes, or clinical treatment. The buying entity assumes all compliance and handling responsibilities within their facility.
